Over the past two decades, biotech and pharmaceutical companies have made significant progress in integrating patient experience data (PED) into the development of new interventions.
This has been facilitated by increased interest from regulatory and payer/access agencies and patient advocacy groups. Now, it’s estimated that more than 90% of registrational clinical trials generate some form of PED.
The recognition of PED as a metric of therapeutic value and the growing role of this data in decision-making during intervention development and beyond is significant and represents positive progress for patient-focused intervention development. However, PED is only one part of a patient-centred approach to drug development.
Check out the rest of the feature here
